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S U M M A R Y
Objectives: To report the incidence, epidemiology, and clinical features of Bordetella pertussis in Peruvian
infants under 1 year old.
Patients and methods: A prospective cross-sectional study was conducted in ﬁve hospitals in Peru from
January 2010 to July 2012. A total of 392 infants under 1 year old were admitted with a clinical diagnosis
of whooping cough and tested for B. pertussis by PCR.
Results: The pertussis toxin and IS481 genes were detected in 39.54% (155/392) of the cases. Infants aged
less than 3 months were the most affected, with a prevalence of 73.55% (114/155). The most common
household contact was the mother, identiﬁed in 20% (31/155) of cases. Paroxysm of coughing (89.03%,
138/155), cyanosis (68.39%, 106/155), respiratory distress (67.09%, 104/155), and breastfeeding
difﬁculties (39.35%, 61/155) were the most frequent symptoms reported.
Conclusion: An increase in pertussis cases has been reported in recent years in Peru, despite national
immunization efforts. Surveillance with PCR for B. pertussis is essential, especially in infants less than
1 year old, in whom a higher rate of disease-related complications and higher mortality have been
reported.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Pertussis is a highly contagious disease of the human
respiratory tract caused by the fastidious Gram-negative cocco-
bacillus Bordetella pertussis. B. pertussis is the primary causative
agent of ‘whooping cough’. It is transmitted person to person and is
characterized by uncontrollable coughing ﬁts, accompanied by
inspiratory stridor.1,2 This classical presentation is well-known,
but has been observed less often since the implementation of
immunization.3
The establishment of pertussis vaccines in the immunization
schedules has reduced the global burden of disease by 90% from
the pre-vaccination stage. However, the re-emergence of this
disease in outbreaks has been observed around the world, both* Corresponding author. Tel.: +51 13133333.
E-mail address: jdelvall@upc.edu.pe (J. del Valle-Mendoza).
http://dx.doi.org/10.1016/j.ijid.2015.10.020
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).in developed and developing countries.4–6 A dramatic increase
in conﬁrmed cases in infants less than 1 year old has also been
reported in recent years.1,5,6 This has raised concerns, especially
for infants younger than 6 months old as they are more
vulnerable to disease-related complications and have a higher
mortality.5,7–9
In Peru, a progressive reduction in pertussis cases was observed
following national immunization efforts in 2004, and in 2010 the
lowest rate of cases was reported in the last 10 years.10 However,
between 2011 and 2012 an abrupt increase of 20 times the
incidence of pertussis cases was registered.11 Furthermore, the
most affected were infants under 1 year old, representing 38% of
cases, despite national immunization coverage of 92% in this age
group.12 Currently, the whole-cell B. pertussis vaccine (DTwP) is the
only available formulation in Peru. According to 2014 epidemiology
reports, the national coverage level for this vaccination, provided
in three doses as part of the pentavalent vaccine (DTwP–Hib–
HepB), was 88.3%.13ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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diagnosis is complicated by the limitations of currently available
diagnostic tests. Multiple factors affect the sensitivity, speciﬁcity,
and interpretation of diagnostic techniques for pertussis. There-
fore, the only diagnostic tests that are accepted to conﬁrm a case
for purposes of national reporting are culture and PCR.6,8 B.
pertussis isolation by culture is the ‘gold standard’ and is essential
for identifying the organism early in the course of disease, but has a
low sensitivity with a reported range between 30% and 60%.8 The
DNA ampliﬁcation techniques (e.g., PCR) for B. pertussis detection
are faster and have increased the sensitivity for the overall
percentage of laboratory-conﬁrmed cases by approximately 19%,
and as such represent the preferred method.14,15 However, in Peru
the use of PCR for surveillance was started only recently (in 2012)
and there is still evidence of inadequate reporting and registration
of cases, which limits the analysis of the real disease burden.12
Studies of the epidemiology of pertussis in Peru are essential in
order to understand the real impact of the disease, especially
following the outbreak in 2012. The aim of this study was to
determine the prevalence and epidemiological and clinical
characteristics of B. pertussis in infants less than 1 year old with
suspected whooping cough in ﬁve hospitals in Peru between
2010 and 2012.
2. Patients and methods
2.1. Study population and design
A prospective cross-sectional study was conducted in ﬁve
hospitals in Lima, Peru from January 2010 to July 2012: Instituto
Nacional de Salud Del Nin˜o, Hospital Edgardo Rebagliati Martin,
Hospital de Emergencias Pedia´tricas, Hospital Nacional Cayetano
Heredia, and the Hospital Regional de Cajamarca in Cajamarca. The
study regions had a representative population, since Lima and
Cajamarca are recognized as B. pertussis endemic areas and have a
vaccine coverage similar to those stated in national reports.
Patients under 1 year old admitted with a probable clinical
diagnosis of whooping cough were included in the study. The
clinical criteria for pertussis were those given in the National
Notiﬁable Diseases Surveillance System (NNDSS) case deﬁnition.
All patients with a chronic pulmonary disease, cardiac disease, or
immunodeﬁciency were excluded.
The project was approved by the Ethics Committee of the
Hospital Nacional Edgardo Rebagliati Martins, Instituto Nacional
de Salud del Nin˜o, and Hospital de Emergencias Pedia´tricas in Lima,
Peru. All samples were analyzed after signed informed consent was
obtained from the children’s parents or caregivers.
2.2. Samples
Nasopharyngeal samples were obtained by inserting a swab
into both nostrils parallel to the palate (calcium alginate swab,
USA). The swabs were placed into the same tube containing 2 ml of
transport solution (PBS 1, phosphate buffered saline). The
samples were then stored at room temperature and sent to the
molecular biology laboratory at Universidad Peruana de Ciencias
Aplicadas (UPC). On receipt of the samples, the swabs were
discarded and the tubes were centrifuged to pellet the cells, which
were then resuspended in 0.8 ml of PBS 1. One aliquot of 200 ml
of each fresh specimen was used for the extraction of nucleic acids.
2.3. DNA extraction
DNA was extracted from a volume of 200 ml of each sample
using a commercial kit (High Pure Template Preparation Kit; Roche
Applied Science, Germany), according to the manufacturer’sinstructions. The DNA obtained was assayed immediately or
stored at 80 8C until use.
2.4. PCR ampliﬁcation
The presence of B. pertussis was determined using two PCR
assays, each speciﬁc for an independent region of the B. pertussis
genome. A 191-bp fragment of the pertussis toxin S1 gene (PTxA)
was ampliﬁed using the primers PTp1 50-CCAACGCGCATGCGTG-
CAGATTCGTC-30 and PTp2 50-CCCTCTGCGTTTTGATGGTGCC-
TATTTTA-30.16 Meanwhile a 145-bp fragment of the insertion
sequence IS481 was ampliﬁed using the primers IS481F 50-
GATTCAATAGGTTGTATGCATGGTT-30 and IS48R 50-TTCAGGCAGA-
CAAACTTGATGGGCG-30.17 The procedures were modiﬁed slightly
as follows: 50 ml of reaction mixture containing 25 ml Ready Mix
Enzyme Solution (Taq polymerase, 2.5 mM MgCl2; 15 mM Tris/HCl
PH 8.3, 50 mM KCl, 200 mM each deoxynucleotide) (Kappa
Biosystems), 20 pmol of each primer (Macrogen, Seoul, Korea),
water, and 5 ml DNA were ampliﬁed in a Verity Thermocycler
(Applied Biosystems, Foster City, CA, USA) using a pre-denatur-
ation step of 5 min at 95 8C, followed by 55 cycles of denaturation
for 1 min at 95 8C, annealing for 1 min at 55 8C, and elongation for
45 s at 72 8C, with a ﬁnal elongation of 10 min at 72 8C. The
presence and size of ampliﬁcation products were analyzed by
electrophoresis on a 2.5% agarose gel (FMC, Rockland, ME, USA)
containing 3 mg/ml of ethidium bromide in 1 Tris-borate buffer
and photographed under ultraviolet illumination (UV Transillumi-
nator KODAC LOGIC 1500, New Haven, USA). All ampliﬁed
products were sequenced (Macrogen, Seoul, Korea).
Samples were determined as positive for B. pertussis when both
the fragment of the pertussis toxin S1 gene (PTxA) and the
insertion sequence IS481 were ampliﬁed, as they have been used
extensively for B. pertussis detection.1,18,19 Other fragments, such
as the pertactin (prn) gene were not considered for ampliﬁcation,
since an increase in pertactin-deﬁcient B. pertussis isolates has
been reported in recent years.20
2.5. Statistical analysis
Qualitative variables were reported as frequencies and per-
centages. A seasonal index was calculated in PCR-conﬁrmed cases
for each month from January 2010 to July 2012. Seasonal indexes
were calculated dividing the monthly frequency of conﬁrmed cases
by the average cases per year.
3. Results
A total of 392 infants under 1 year old diagnosed with whooping
cough from January 2010 to July 2012 were included. The pertussis
toxin and IS481 genes were detected in 39.54% (155/392) of the
cases. Among all PCR-conﬁrmed cases, infants under 3 months of
age were the most affected, with a prevalence of 73.55% (114/155),
and a similar sex distribution was observed. A signiﬁcant number
of 120 household contacts were identiﬁed by PCR, with the mother
most frequently reported (20%, 31/155), followed by brothers older
than 10 years old (19.35%, 30/155) and uncles (18.71%, 29/155)
(Table 1).
The most common symptoms in patients with positive B.
pertussis were paroxysm of coughing (89.03%, 138/155), cyanosis
(68.39%, 106/155), respiratory distress (67.09%, 104/155), breast-
feeding difﬁculties (39.35%, 61/155), and fever (34.19%, 53/155). In
patients under 3 months of age, breastfeeding difﬁculties (44.7%,
51/144), apnea (21.05%, 24/144), and redness (78.07%, 89/144)
were more commonly observed. Furthermore, episodes of diarrhea
(17.07%, 7/41) and post-tussive emesis (60.97%, 25/41) were more
frequent in infants older than 3 months of age (Table 2).
Table 1
General characteristics of Bordetella pertussis cases
Characteristic Total patients Patients positive for B.
pertussis by PCR (%)
Frequency
(n = 392)
Prevalence
(%)
Frequency
(n = 155)
Prevalence
(%)
Sex distribution
Female 169 43.11 71 45.81
Male 223 56.89 84 54.19
Age
3 months 266 67.86 114 73.55
>3 months 126 32.14 41 26.45
Household contacts
Mother 63 16.07 31 20
Father 23 5.87 6 3.87
Brother 10 years 71 18.11 11 7.1
Brother 10 years 26 6.63 30 19.35
Uncle 39 9.95 29 18.71
Others 43 10.97 13 8.39
Not indicated 127 32.4 35 22.58
Table 3
Complications in hospitalized infants with conﬁrmed Bordetella pertussis
Complications Total patients positive for B.
pertussis by PCR (n = 155)
Total, n (%)
 3 months
(n = 114)
>3 months
(n = 41)
155 (100)
ABOS 59 (51.75) 22 (53.66) 81 (52.22)
Pneumonia 28 (24.56) 8 (19.51) 36 (23.22)
Atelectasis 8 (7.02) 2 (4.87) 10 (6.45)
Seizures 1 (0.88) 0 (0) 1 (0.65)
Umbilical/inguinal hernia 6 (5.26) 0 (0) 6 (3.87)
ICU admission 11 (9.65) 3 (7.31) 14 (9.03)
Death 6 (5.26) 3 (7.31) 9 (5.81)
ABOS, acute bronchial obstructive syndrome; ICU, intensive care unit.
Table 4
Complete blood count (CBC) in infants with Bordetella pertussis
Hemogram Total patients positive for B.
pertussis (n = 155)
Total, n (%)
3 months
(n = 114)
>3 months
(n = 41)
155
Leukocytosis (>18  109/mm3) 31 (27.19) 7 (17.07) 38 (24.52)
Lymphocytosis 50 (43.86) 11 (26.82) 61(39.35)
Normal 33 (28.95) 23 (56.09) 56 (36.13)
Table 5
Deaths of infants hospitalized with Bordetella pertussis (PCR-positive)
No. Age, months Leukocytes (109/mm3) Cause of death
1 1.6 28 000 Sepsis
2 2 8720 Pneumonia, sepsis
3 1 6000 Pneumonia, sepsis
4 4 ND Sepsis
5 6 5200 Pneumonia, sepsis
6 5 6800 Pneumonia, atelectasis, ARSD
7 1 25 700 Pneumonia, myocarditis
8 < 1 44 210 Pneumonia, sepsis
9 1 39 600 Pneumonia, PH, MOD
ND, not determined; ARSD, acute respiratory distress syndrome; PH, pulmonary
hypertension; MOD, mutiple organ dysfuntion.
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(ABOS) and pneumonia were present in 52.22% (81/155) and
23.22% (36/155) of the cases, respectively. Intensive care unit (ICU)
admission (9.03%, 14/155) and atelectasis (6.45%, 10/155) were
less frequently reported complications (Table 3).
Regarding blood samples from patients with a positive PCR for
B. pertussis, the presence of leukocytosis was reported in 24.52%
(38/155) and lymphocytosis in 39.35% (61/155) of cases. Both of
these laboratory abnormalities were more commonly observed in
children under 3 months of age (Table 4).
A total of 10 deaths were registered during hospitalization, with
nine infants being PCR-conﬁrmed cases. The most common
reported causes of death were pneumonia and sepsis. A very high
leukocytosis was observed in four out of nine cases (Table 5).
Most hospitalized infants with whooping cough were admitted
during the summer and autumn months (Figure 1). A seasonal
index was calculated for PCR-conﬁrmed cases during the 3 years of
the study, and the highest index was registered during the period
February to May, with an average between 1.19 and 1.38 (Figure 2).
4. Discussion
Bordetella pertussis is a strict human pathogen that causes
whooping cough, an endemic illness responsible for signiﬁcant
morbidity and mortality, especially in infants under 6 months
old.1,2,5 In recent years, a re-emergence of pertussis has been
noted, even in countries with high vaccination coverage.4,5,21 InTable 2
Clinical symptoms in PCR conﬁrmed cases of Bordetella pertussis
Clinical symptoms Patients positive for B. pertussis by PCR
3 months >
Frequency
(n = 114)
Prevalence
(%)
F
(
Paroxysm of coughing 98 85.96 4
Cyanosis 79 69.2 2
Respiratory distress 76 66.6 2
Fever 35 30.7 1
Breastfeeding difﬁculties 51 44.7 1
Apnea 24 21.05 
Ruddiness 89 78.07 2
Diarrhea 10 8.77 
Post-tussive emesis 53 46.49 2
Inspiratory stridor 27 23.68 1
Disease onset before hospitalization:
14 days 73 64.03 2
>14 days 35 30.70 1Peru, an alarming increase in cases has been observed since
2011, and in 2012 an outbreak was reported in most regions,
affecting primarily infants under 1 year old.10–12 The most
affected regions were Loreto, Ucayali, Lima, Cajamarca, Ayacu-
cho, and Amazonas, where the highest incidences of pertussis
were registered.10 Thus active surveillance is required to
accurately measure the disease impact on these communities,
as well as vaccine efﬁcacy.223 months Total
requency
n = 41)
Prevalence
(%)
Frequency
(n = 155)
Prevalence
(%)
0 97.56 138 89.03
7 65.85 106 68.39
8 68.29 104 67.09
8 43.9 53 34.19
0 24.39 61 39.35
6 14.63 30 19.35
4 58.54 113 72.9
7 17.07 17 10.97
5 60.97 78 50.32
1 26.83 38 24.52
1 51.22 94 60.64
7 41.46 53 34.19
Figure 1. Bordetella pertussis seasonal distribution (January 2009–July 2012).
Figure 2. Seasonal index in Bordetella pertussis conﬁrmed cases (January 2010–July 2012).
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demonstrated in infants less than 1 year old, and outbreaks have
been observed in the last 10 years.6 A study in Argentina from
2003 to 2011 reported an incidence of pertussis as high as 80.3%
of cases in infants younger than 6 months old.5 Another study in
Panama´, performed in children under 14 years old, reported
that in 2012, infants under 3 months of age represented the
highest percentage of cases at 74.8%.23 In Peru, a study
conducted from 2003 to 2008 in infants less than 6 months
of age reported that infants under 3 months old were more
frequently affected in 77.6% of cases.24 In the present series,
73.55% of infants with a PCR-conﬁrmed test were under
3 months old.
The alarming increase in cases in very young infants who are
unimmunized or partially immunized is of particular concern,
since this age group is more vulnerable to disease-related
complications and has a higher mortality.7,8,25 Several factors
are proposed to explain this phenomenon: post-vaccine immunity
loss in household contacts, transmission from vaccinated asymp-
tomatic individuals who remain infectious, implementation of
molecular methods for diagnosis, improvements in epidemiologi-
cal surveillance systems, a reduction in vaccine efﬁcacy, and even
genetic changes in the bacteria.26–29Since most infants are infected before vaccination and
concomitant protection is completed, household contacts repre-
sent an important factor in B. pertussis outbreaks.9 Adults and
adolescents have been identiﬁed as the most important sources of
infection, since immunity is diminished or lost in this group and
atypical clinical presentations are more common.25,26,29,30 A study
conducted in infants under 1 year old admitted to a pediatric ICU,
identiﬁed the mothers as the most common source of pertussis
infection in 50% of cases, followed by another adult in 20%, siblings
in 17%, and fathers in 10%.9 A previous study in infants under
6 months of age from Lima, Peru found siblings under 12 years of
age to be the most frequent household contact in 40.5% of cases,
followed by mothers and fathers in 36.5% and 11.7%, respective-
ly.24 In the present series, a total of 120 household contacts were
identiﬁed by PCR, with the mothers also reported most frequently
(20% of cases), followed by brothers older than 10 years old
(19.35%) and uncles (18.71%).
The most common clinical manifestations of B. pertussis
infection are prolonged and paroxysmal coughing, accompanied
by inspiratory stridor.1,2 Nevertheless, several factors are known to
affect the presentation of the disease, including patient age,
previous immunization or infection, presence of passively acquired
antibody, and antibiotic treatment.30Multiple series have reported
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respiratory distress (47.8–55.7%) as the most common symptoms
in children.5,23,24 In the present study, a similar frequency of these
three symptoms was found: paroxysm of coughing in 89.03%,
cyanosis in 68.39%, and respiratory distress in 67.09%. Infants
under 3 months old represented 73.55% of cases, and this might
explain why breastfeeding difﬁculties, cyanosis, apnea, and
ruddiness were frequently reported.
The presence of pneumonia has been identiﬁed as the main
complication in hospitalized patients with whooping cough,
especially in infants under 1 year old.1,30 In the USA and Canada,
pneumonia is the most common cause of death and has been
observed in 5.2% and 9.4% of patients, respectively.31–34 Further-
more, a higher rate of cases complicated with pneumonia has been
reported in Latin America, ranging from 9.0% to 25.6% of cases.23–25
In the present study population, pneumonia was the second most
common complication and was observed in 24.56% of infants
under 3 months old.
The presence of leukocytosis and lymphocytosis has frequently
been reported in conﬁrmed cases of pertussis.23 In addition, a
leukocyte count 20  109/mm3 is commonly associated with
pertussis infection and a count above 30  109/mm3 is an
independent predictor of mortality.5 In the present study,
leukocytosis was reported in 24.52% of cases and lymphocytosis
in 39.35% of cases. The most common causes of death reported
were pneumonia and sepsis, and a very high leukocytosis was
observed in four out of nine cases.
With regard to B. pertussis seasonality, a pattern corresponding
to the summer and spring months has been reported in the
southern hemisphere.5 Similarly, a previous study in infants under
6 months of age performed from 2003 to 2008 in Lima, registered
more hospitalizations due to whooping cough during the months
of February and September. In the present study, most of the
hospitalized infants were admitted during the summer and
autumn months. Furthermore, a higher seasonal index was
observed during the period from February to May. This pattern
may differ slightly from previous reports, since this surveillance
study included the 2012 outbreak in Peru.
Pertussis is an endemic vaccine-preventable disease and a
major health problem in Peru. Current national vaccination
strategies focus only on children and appear insufﬁcient to prevent
death in young infants. Thus, the viability of new strategies must
be analyzed to include vaccination in newborns, adolescents, the
elderly, health care workers, and pregnant women.
Recent evidence suggests that maternal immunization with
acellular pertussis during pregnancy is safe and highly effective at
protecting infants from pertussis, and that it may also have a high
impact on morbidity and mortality in infants too young to have
been immunized. Thus, the vaccination of pregnant women is
considered likely to be the most cost-effective complementary
strategy to prevent pertussis-associated infant mortality.6
Continued strengthening of pertussis surveillance in Peru is
essential. In addition, the use of molecular techniques (e.g. PCR)
should be encouraged for national epidemiology reporting, in
order to evaluate the reliability of the data on the incidence, case-
fatality, age distribution, proportion of conﬁrmed cases, and
vaccine efﬁcacy.
In conclusion, there has been a resurgence of B. pertussis in Peru.
The pertussis toxin and IS481 genes were detected in 39.54% of
cases presenting between January 2010 and July 2012. Infants
under 3 months of age were the most affected at 73.55% of cases,
and the disease was reported more commonly during the summer
and autumn. The mother was the most frequent household
contact, reported in 20% of cases, followed by brothers older than
10 years old in 19.35% and uncles in 18.71%. ABOS and pneumonia
were present in 52.22% and 23.22% of the cases, respectively. Thecase-fatality rate in the present series of patients was 5.8%, with a
median age of 2.5 months.
Acknowledgements
This work was supported by Sanoﬁ Aventis del Peru.
Conﬂict of interest: On behalf of all authors, the corresponding
author states that there are no conﬂicts of interest or funding
related to this study
References
1. Torres R, Santos T, Torres R, Pereyra W, Fa´vero LA, Filho OR, et al. Resurgence of
pertussis at the age of vaccination: clinical, epidemiological, and molecular
aspects. J Pediatr (Rio J) 2015;91:333–8.
2. Centers for Disease Control and Prevention (CDC). Childhood whooping cough
vaccine protects most children for at least 5 years. Atlanta, GA: CDC; 2015. Avail-
able at: http://www.cdc.gov/pertussis/surv-reporting.html (accessed June 18,
2015).
3. Van den Brink G, Wishaupt J, Douma J, Hartwig NG, Versteegh FG. Bordetella
pertussis: an underreported pathogen in pediatric respiratory infections, a
prospective cohort study. BMC Infect Dis 2014; 30;14:526.
4. World Health Organization (WHO). Pertussis vaccines: WHO position paper.
Geneva, Switzerland: WHO; 2015. Available at: http://www.who.int/wer/2010/
wer8540.pdf?ua=1. (accessed July 8, 2015).
5. Gentile A, Romanin V, Juarez Mdel V, Lucio¨n MF, Romanin VS, Giglio N, Bakin J.
Epidemiology of Bordetella pertussis in a children’s hospital. Arch Argent Pediatr
2014;112:26–32.
6. Pan American Health Organization (PAHO). Alerta epidemiolo´gica: Tos Ferina
(Coqueluche). Washington, DC: PAHO; 2015. Available at: http://www.paho.
org/hq/index.php?option=com_docman&task=doc_view&gid=19325&Itemid
(accessed May 22, 2015).
7. Tan T, Trindade E, Skowronski D. Epidemiology of pertussis. Pediatr Infect Dis J
2005;24(5 Suppl):S10–8.
8. Murphy T, Slade B, Broder K, Kretsinger K, Tiwari T, Joyce PM, et al. Prevention of
pertussis, tetanus and diphtheria among pregnant and postpartum women and
their infants: recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep 2008;57(RR-4):1–51.
9. Kowalzik F, Barbosa A, Fernandes V, Carvalho PR, Avila-Aguero ML, Goh DY,
et al. Prospective multinational study of pertussis infection in hospitalized
infants and their household contacts. Pediatr Infect Dis J 2007;26:238–42.
10. Red Nacional de Epidemiologia (RENACE). Distribucio´n de Tos Ferina por
distritos Peru 2015. Lima, Peru´: RENACE, Direccio´n General de Epidemiologı´a
(DGE); 2015. Available at: http://www.dge.gob.pe/portal/docs/vigilancia/sala/
2015/SE23/tosf.pdf (accessed June 12, 2015).
11. Ministerio de Salud del Peru (MINSA). Alerta epidemiolo´gica: Brote de Tos
Ferina en el Paı´s. Lima, Peru: MINSA, Direccio´n General de Epidemiologı´a (DGE);
2015. Available at: http://www.inr.gob.pe/transparencia/Epidemiolog%
C3%ADa/alertas%20epidemiologicas/ALERTA%20N%C2%BA%2003%20BROTE%
20DE%20TOS%20FERINA.pdf (accessed June 12, 2015).
12. Ministerio de Salud del Peru (MINSA). Boletı´n epidemiolo´gico 06. Lima, Peru:
MINSA, Direccio´n General de Epidemiologı´a (DGE); 2015. Available at: http://
www.dge.gob.pe/portal/docs/vigilancia/boletines/2015/06.pdf.(accessed June
22, 2015).
13. Oﬁcina General de Epidemiologia e Informa´tica (OGEI), Ministerio de Salud
(MINSA). Boletı´n: Bordetella pertussis. Lima, Peru: OGEI, MINSA; 2015.(unpub-
lished report).
14. Hajia M, Rahbar M, Fallah F. Detection of Bordetella pertussis in infants sus-
pected to have whooping cough. Open Respir Med J 2012;6:34–6.
15. Riffelmann M, Wirsing von Ko¨nig C, Caro V, Guiso N, Pertussis PCR Consesus
Group. Nucleic acid ampliﬁcation tests for diagnosis of Bordetella infections. J
Clin Microbiol 2005;43:4925–9.
16. Houard S, Hackel C, Herzog A, Bollen A. Speciﬁc identiﬁcation of Bordetella
pertussis by the polymerase chain reaction. Res Microbiol 1989;140:477–87.
17. Glare EM, Paton JC, Premier RR, Lawrence AJ, Nisbet IT. Analysis of a repetitive
DNA sequence from Bordetella pertussis and its application to the diagnosis of
pertussis using the polymerase chain reaction. J Clin Microbiol 1990;28:1982–7.
18. Kolodkina V, Martinov V, Babenko A. Multiplex real-time PCR assay for detec-
tion and differentiation of Bordetella pertussis and Bordetella parapertussis. Iran J
Microbiol 2014;6:140–8.
19. Jerris R, Williams S, MacDonald H, Ingebrigtsen DR, Westblade LF, Rogers BB.
Testing implications of varying targets for Bordetella pertussis: comparison of
the FilmArray Respiratory Panel and the Focus B. pertussis PCR assay. J Clin
Pathol 2015;68:394–6.
20. Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, et al. Rapid
increase in pertactin-deﬁcient Bordetella pertussis isolates. Australia Emerg
Infect Dis 2014;20:626–33.
21. Gao F, Mahoney J, Daly E, Lamothe W, Tullo D, Bean C. Evaluation of a multi-
target real-time PCR assay for detection of Bordetella species during a pertussis
outbreak in New Hampshire in 2011. J Clin Microbiol 2014;52:302–6.
22. Knorr L, Fox J, Tilley P, Ahmed-Bentley J. Evaluation of real-time PCR for
diagnosis of Bordetella pertussis infection. BMC Infect Dis 2006; 23;6:62.
M.E. Castillo et al. / International Journal of Infectious Diseases 41 (2015) 36–41 4123. Nieto-Guevara J, Luciani K, Montesdeoca-Melian, Mateos Dura´n M, Estripeaut
D. Hospital admissions due to whooping cough: experience of the Del Nin˜o
Hospital in Panama, period 2001–2008. An Pediatr (Barc) 2010;72:172–8.
24. Castillo M, Petrozzi V, Vera M. Study clinical and epidemiological of whooping
cough in breastfed babies under 6 months admitted in three hospitals of Lima,
Peru over the years 2003-2008. Rev Peru Pediatr 2012;65:21–32.
25. Quian J, Cerisola A, Russomano F, Ferna´ndez A, Cappeta Te´cM, Uriarte DresR,
et al. Infecciones por Bordetella pertussis en nin˜os menores de un an˜o hospi-
talizados y sus contactos en el hogar. Arch Pediatr Urug 2006;77:229–36.
26. Nikbin V, Shahcheraghi, Lotﬁ M, Zahraei SM, Parzadeh M. Comparison of culture
and real-time PCR for detection of Bordetella pertussis isolated from patients in
Iran. Iran J Microbiol 2013;5:209–14.
27. Centers for Disease Control and Prevention (CDC). About pertussis outbreaks.
Atlanta: CDC; 2014. Available at: http://www.cdc.gov/pertussis/outbreaks/
about.html (accessed September 22, 2014).
28. Althouse BM, Scarpino SV. Asymptomatic transmission and the resurgence of
Bordetella pertussis. BMC Med 2015;13:146.29. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect
against disease but fail to prevent infection and transmission in a nonhuman
primate model. Proc Natl Acad Sci U S A 2014;111:787–92.
30. Crowcroft N, Booy R, Harrison T, Spicer L, Britto J, Mok Q, et al. Severe and
unrecognised: pertussis in UK infants. Arch Dis Child 2003;88:802–6.
31. Perret C, Viviani T, Pen˜a A, Abarca K, Ferre´s M. Source of infection in young
infants hospitalized with Bordetella pertussis. Rev Med Chile 2011;139:448–54.
32. Matto S, Cherry J. Molecular pathogenesis, epidemiology, and clinical mani-
festations of respiratory infections due to Bordetella pertussis and other Borde-
tella subspecies. Clin Microbiol Rev 2005;18:326–82.
33. Centers for Disease Control, Prevention (CDC). Pertussis—United States, 1997–
2000. MMWR Morb Mortal Wkly Rep 2002;51:73–6.
34. Halperin SA, Wang EE, Law B, Mills E, Morris R, De´ry P, et al. Epidemiological
features of pertussis in hospitalized patients in Canada, 1991-1997: report of
the Immunization Monitoring Program–Active (IMPACT). Clin Infect Dis
1999;28:1238–43.
